Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE II 8 5 versus FREAMINE III 8 5 W ELECTROLYTES.
FREAMINE II 8.5% vs FREAMINE III 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE II 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, supporting nitrogen balance and tissue repair in patients unable to tolerate oral or enteral nutrition.
FREAMINE III 8.5% W/ ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue maintenance in patients unable to tolerate oral/enteral nutrition.
Intravenous infusion: 0.8-1.5 g amino acids/kg/day. Typical dose is 500-1000 mL per day (42.5-85 g amino acids). Infusion rate should not exceed 0.1 g amino acids/kg/hour.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (equivalent to 12-18 mL/kg/day of 8.5% solution). Administer via central or peripheral line. Typical adult dose: 500-1000 mL/day infused at 125-200 mL/hour.
None Documented
None Documented
Not applicable as a mixture; individual amino acids have variable half-lives (e.g., essential amino acids ~1-3 hours). Clinical context: continuous infusion required to maintain plasma levels.
Not applicable as a composite mixture; individual amino acid half-lives vary from minutes to hours. Clinical context: continuous infusion used for metabolic support.
Renal elimination of nitrogenous waste products (urea) derived from amino acid metabolism; <5% excreted unchanged in urine. No significant biliary or fecal elimination.
Renal (primarily as urea and ammonia); 100% of infused amino acids are metabolized or excreted renally. Fecal excretion negligible.
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid